Predilife (XPAR:ALPRE) Change In Receivables : €0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Predilife Change In Receivables?

Predilife's change in receivables for the quarter that ended in Jun. 2023 was €0.00 Mil. It means Predilife's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

Predilife's change in receivables for the fiscal year that ended in Dec. 2022 was €0.00 Mil. It means Predilife's Accounts Receivable stayed the same from Dec. 2021 to Dec. 2022 .

Predilife's Accounts Receivable for the quarter that ended in Jun. 2023 was €0.07 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Predilife's Days Sales Outstanding for the six months ended in Jun. 2023 was 76.32.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Predilife's liquidation value for the six months ended in Jun. 2023 was €-6.15 Mil.

Predilife Change In Receivables Historical Data

The historical data trend for Predilife's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Change In Receivables Chart

Predilife Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

Predilife Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial									-	-	-	-	-

Predilife Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Predilife (XPAR:ALPRE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Predilife's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.069	/	0.165	*	91
=	76.32

2. In Ben Graham's calculation of liquidation value, Predilife's accounts receivable are only considered to be worth 75% of book value:

Predilife's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.375	-	9.581	+	0.75 * 0.069	+	0.5 * 0
=	-6.15

Predilife Change In Receivables Related Terms

Thank you for viewing the detailed overview of Predilife's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Predilife (XPAR:ALPRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800

Website

https://www.predilife.com

Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines